Amalgamated Bank’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Amalgamated Bank’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,144	Closed	-$8K	–	2720
2025 Q4	$8K	Buy	2,144 +128	+6%	+$475	﹤0.01%	2544
2025 Q3	$7K	Hold	2,016	–	–	﹤0.01%	2636
2025 Q2	$4K	Buy	+2,016	New	+$5.04K	﹤0.01%	2885
2023 Q2	–	Sell	-5,104	Closed	-$3K	–	3120
2023 Q1	$3K	Buy	5,104 +241	+5%	+$307	﹤0.01%	2927
2022 Q4	$8K	Hold	4,863	–	–	﹤0.01%	2902
2022 Q3	$23K	Buy	4,863 +1,894	+64%	+$11.1K	﹤0.01%	2780
2022 Q2	$15K	Buy	+2,969	New	+$21.6K	﹤0.01%	2921

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Bank's STLN Position: Q1 2026 in Review

Amalgamated Bank sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026, closing a stake of 2,144 shares — an estimated $8K sold.

Amalgamated Bank first reported a position in STLN in Q2 2022 and held it in 7 quarters. The position peaked at $23K in Q3 2022. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

Amalgamated Bank reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
Amalgamated Bank sold 2,144 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $8K.
Amalgamated Bank first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
Amalgamated Bank's Starling Oncology Institute, Inc. Common Stock position peaked at $23K in Q3 2022.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.